#BEGIN_DRUGCARD DB05259

# AHFS_Codes:
Not Available

# ATC_Codes:
L03AX13

# Absorption:
Not Available

# Biotransformation:
Hydrolyzed by proteases

# Brand_Mixtures:
Not Available

# Brand_Names:
Copaxone

# CAS_Registry_Number:
147245-92-9

# ChEBI_ID:
Not Available

# Chemical_Formula:
C25H45N5O13

# Chemical_IUPAC_Name:
Not Available

# Chemical_Structure:
Not Available

# Creation_Date:
2007-11-18 11:22:49 -0700

# DPD_Drug_ID_Number:
2233014

# Description:
Glatiramer acetate consists of the acetate salts of synthetic polypeptides, containing four naturally occurring amino acids: L-glutamic acid, L-alanine, L-tyrosine, and L-lysine with an average molar fraction of 0.141, 0.427, 0.095, and 0.338, respectively. The average molecular weight of glatiramer acetate is 5,000-9,000 daltons.  It is an immunomodulator, licensed in much of the world for reduced frequency of relapses in relapsing-remitting multiple sclerosis

# Dosage_Forms:
Powder, for solution	Subcutaneous
Solution	Subcutaneous

# Drug_Category:
Adjuvants, Immunologic
Immunosuppressive Agents

# Drug_Interactions:
Rilonacept	results in increased immunosuppressive effects; increases the risk of infection.

# Drug_Reference:
11501229	Francis DA: Glatiramer acetate (Copaxone). Int J Clin Pract. 2001 Jul-Aug;55(6):394-8.
15371592	Arnon R, Aharoni R: Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications. Proc Natl Acad Sci U S A. 2004 Oct 5;101 Suppl 2:14593-8. Epub 2004 Sep 15.
17920545	Weber MS, Hohlfeld R, Zamvil SS: Mechanism of action of glatiramer acetate in treatment of multiple sclerosis. Neurotherapeutics. 2007 Oct;4(4):647-53.
9548401	Li Q, Milo R, Panitch H, Swoveland P, Bever CT Jr: Glatiramer acetate blocks the activation of THP-1 cells by interferon-gamma. Eur J Pharmacol. 1998 Jan 26;342(2-3):303-10.

# Drug_Type:
Approved
Biotech
Investigational

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Glatiramer Acetate

# HET_ID:
Not Available

# Half_Life:
Not Available

# InChI_Identifier:
Not Available

# InChI_Key:
Not Available

# Indication:
For reduction of the frequency of relapses in patients with Relapsing-Remitting Multiple Sclerosis.

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
5260

# Mechanism_Of_Action:
Glatiramer acetate (GA) exhibits strong and promiscuous binding to MHC molecules (HLA DRB1* variants) and consequent competition with various myelin antigens for their presentation to T cells. A further aspect of its action is potent induction of specific suppressor cells of the T helper 2 (Th2) type that migrate to the brain and lead to in situ bystander suppression. Furthermore, the GA-specific cells in the brain express the anti-inflammatory cytokines IL-10 and transforming growth factor beta, in addition to brain-derived neurotrophic factor, whereas they do not express the inflammatory cytokine IFN-gamma. Recent evidence also suggests that Glatiramer acetate directly inhibits dendritic cells and monocytes - both of which are circulating antigen presenting cells.

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
623.6505

# Molecular_Weight_Mono:
Not Available

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA449760

# Pharmacology:
Glatiramer acetate was originally designed to mimic a protein in myelin, called myelin basic protein, with the intention of inducing EAE (an animal model of MS). Quite to the contrary, it was found to suppress the disease and as a result came to be trialed in human MS. There is some evidence that Glatiramer acetate converts the body's immune response from a Th1 type to a Th2 one, promotes suppressor T cells or acts as an altered peptide ligand. Studies in animals and in vitro systems suggest that upon its administration, glatiramer acetate-specific suppressor T-cells are induced and activated in the periphery. Some fraction of the injected material, either intact or partially hydrolyzed, is presumed to enter the lymphatic circulation, enabling it to reach regional lymph nodes, and some may enter the systemic circulation intact.

# Predicted_LogP_Hydrophobicity:
Not Available

# Predicted_LogS:
Not Available

# Predicted_Water_Solubility:
Not Available

# Primary_Accession_No:
DB05259

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
Not Available

# PubChem_Substance_ID:
Not Available

# RxList_Link:
http://www.rxlist.com/cgi/generic/glatiramer.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD00999

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
Not Available

# State:
liquid

# Structure:
0

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
COP-1
Copolymer-1
Copoylmer 1

# Synthesis_Reference:
Not Available

# Toxicity:
Adverse reactions include injection site reactions, vasodilatation, chest pain, asthenia, infection, pain, nausea, arthralgia, anxiety, and hypertonia.

# Update_Date:
2012-06-14 15:25:21 -0600

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Glatiramer_acetate

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Membrane

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
11752352	Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
15371592	Arnon R, Aharoni R: Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications. Proc Natl Acad Sci U S A. 2004 Oct 5;101 Suppl 2:14593-8. Epub 2004 Sep 15.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
HLA-DRB1

# Drug_Target_1_GenBank_ID_Gene:
M11161

# Drug_Target_1_GenBank_ID_Protein:
Not Available

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
HLA-DRB1

# Drug_Target_1_Gene_Sequence:
>801 bp
ATGGTGTGTCTGAAGCTCCCTGGAGGCTCCTGCATGACAGCGCTGACAGTGACACTGATG
GTGCTGAGCTCCCGACTGGCTTTGGCTGGGGACACCCGACCACGTTTCTTGTGGCAGCTT
AAGTTTGAATGTCATTTCTTCAATGGGACGGAGCGGGTGCGGTTGCTGGAAAGATGCATC
TATAACCAAGAGGAGTCCGTGCGCTTCGACAGCGACGTGGGGGAGTACCGGGCGGTTGAG
GAGCTGGGGCGGCCTGATGCCGAGTACTGGAACAGCCAGAAGGACCTCCTGGAGCAGAAG
CGGGGCCAGGTGGACAATTACTGCAGACACAACTACGGGGTTGGTGAGAGCTTCACAGTG
CAGCGGCGAGTTGAGCCTAAGGTGACTGTGTATCCTTCAAAGACCCAGCCCCTGCAGCAC
CACAACCTCCTGGTCTGCTCTGTGAGTGGTTTCTATCCAGGCAGCATTGAAGTCAGGTGG
TTCCGGAACGGCCAGGAAGAGAAGGCTGGGGTGGTGTCCACGGGCCTGATCCAGAATGGA
GATTGGACCTTCCAGACCCTGGTGATGCTGGAAATAGTTCCTCGGAGTGGAGAGGTTTAC
ACCTGCCAAGTGGAGCACCCAAGTGTGACGAGCCCTCTCACAGTGGAATGGAGAGCACGG
TCTGAATCTGCACAGAGCAAGATGCTGAGTGGAGTCGGGGGCTTCGTGCTGGGCCTGCTC
TTCCTTGGGGCCGGGCTGTTCATCTACTTCAGGAATCAGAAAGGACACTCTGGACTTCAG
CCAACAGGATTCCTGAGCTGA

# Drug_Target_1_General_Function:
Not Available

# Drug_Target_1_General_References:
10203026	Palou E, Mongay L, Arias MT, Isart F, Suarez B, Masso M, Fabregat V, Martorell J, Gaya A: Identification of a novel DRB1-allele (DRB1*0106) by sequence-based typing. Tissue Antigens. 1999 Mar;53(3):308-10.
1688595	Coppin HL, Avoustin P, Fabron J, Huchenq A, Garnier JM, Thomsen M, De Preval C: Evolution of the HLA-DR1 gene family. Structural and functional analysis of the new allele "DR-BON". J Immunol. 1990 Feb 1;144(3):984-9.
2453563	Hurley CK, Ziff BL, Silver J, Gregersen PK, Hartzman R, Johnson AH: Polymorphism of the HLA-DR1 haplotype in American blacks. Identification of a DR1 beta-chain determinant recognized in the mixed lymphocyte reaction. J Immunol. 1988 Jun 1;140(11):4019-23.
2998758	Tonnelle C, DeMars R, Long EO: DO beta: a new beta chain gene in HLA-D with a distinct regulation of expression. EMBO J. 1985 Nov;4(11):2839-47.
3858829	Bell JI, Estess P, St John T, Saiki R, Watling DL, Erlich HA, McDevitt HO: DNA sequence and characterization of human class II major histocompatibility complex beta chains from the DR1 haplotype. Proc Natl Acad Sci U S A. 1985 May;82(10):3405-9.
8462990	Louis P, Eliaou JF, Kerlan-Candon S, Pinet V, Vincent R, Clot J: Polymorphism in the regulatory region of HLA-DRB genes correlating with haplotype evolution. Immunogenetics. 1993;38(1):21-6.

# Drug_Target_1_HGNC_ID:
HGNC:4948

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
4183

# Drug_Target_1_Locus:
6p21.3

# Drug_Target_1_Molecular_Weight:
29914

# Drug_Target_1_Name:
HLA class II histocompatibility antigen, DRB1-1 beta chain

# Drug_Target_1_Number_of_Residues:
266

# Drug_Target_1_PDB_ID:
1AQD

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00969	MHC_II_beta
PF07654	C1-set

# Drug_Target_1_Protein_Sequence:
>HLA class II histocompatibility antigen, DRB1-1 beta chain
MVCLKLPGGSCMTALTVTLMVLSSPLALAGDTRPRFLWQLKFECHFFNGTERVRLLERCI
YNQEESVRFDSDVGEYRAVTELGRPDAEYWNSQKDLLEQRRAAVDTYCRHNYGVGESFTV
QRRVEPKVTVYPSKTQPLQHHNLLVCSVSGFYPGSIEVRWFRNGQEEKAGVVSTGLIQNG
DWTFQTLVMLETVPRSGEVYTCQVEHPSVTSPLTVEWRARSESAQSKMLSGVGGFVLGLL
FLGAGLFIYFRNQKGHSGLQPTGFLS

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
1-29

# Drug_Target_1_Specific_Function:
Not Available

# Drug_Target_1_SwissProt_ID:
P04229

# Drug_Target_1_SwissProt_Name:
2B11_HUMAN

# Drug_Target_1_Synonyms:
DR-1
DR1
HLA class II histocompatibility antigen, DRB1-1 beta chain precursor
MHC class I antigen DRB1*1

# Drug_Target_1_Theoretical_pI:
7.78

# Drug_Target_1_Transmembrane_Regions:
228-250

#END_DRUGCARD DB05259
